NT026

NT026 is a preclinical radioligand therapy (RLT) candidate being developed by Chengdu New Radiomedicine Technology for the treatment of solid tumors. As of 2024, the program is in the "Hits" stage of discovery, which represents the earliest phase of preclinical development. The specific molecular target and the therapeutic radioisotope utilized in the conjugate have not been publicly disclosed by the developer. The therapy is designed to selectively bind to tumor-associated antigens to deliver localized ionizing radiation, aiming to induce DNA damage and cell death in malignant tissues while minimizing off-target effects to healthy organs.